Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy

PURPOSE: Although several molecular markers predicting resistance to cetuximab- or panitumumab-based therapy of metastatic colorectal cancer were described, mutations in RAS proto-oncogenes remain the only predictors being used in daily clinical practice. However, 35%–45% of wild-type RAS patients s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Onco Targets Ther
Autores principales: Nemecek, Radim, Berkovcova, Jitka, Radova, Lenka, Kazda, Tomas, Mlcochova, Jitka, Vychytilova-Faltejskova, Petra, Slaby, Ondrej, Svoboda, Marek
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4968864/
https://ncbi.nlm.nih.gov/pubmed/27555788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S102891
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares